Author | Matthew D. Galsky, MD | OncLive

Author | Matthew D. Galsky, MD


Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer

August 06, 2019

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 07, 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.